SCHEMBL3598595

SCHEMBL3598595

Cc1cccc(OC(C)C(=O)c2ccc(C(C)C)cc2)c1C

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 1/20 0.41
▸ POLB P06746 1/20 0.40
▸ LMNA P02545 3/20 0.40
▸ L3MBTL1 Q9Y468 3/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ CYP2C9 P11712 2/20 0.40
▸ TSHR P16473 1/20 0.38
▸ NPC1 O15118 1/20 0.37
▸ HPGD P15428 2/20 0.36
▸ XBP1 P17861 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ AR P10275 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3603189 0.83 MEN1 (0.43) MAPTMEN1KMT2ACYP2C9TSHR
SCHEMBL16234636 0.77 TSHR (0.46) POLBLMNAL3MBTL1RAB9AMAPT
SCHEMBL13395961 0.70 MEN1 (0.45) MEN1KMT2AHPGDXBP1ALDH1A1
SCHEMBL7757971 0.70 MAPT (0.40) TP53POLBL3MBTL1RAB9AMAPT
SCHEMBL516150 0.69 MAPT (0.44) POLBLMNAL3MBTL1RAB9AMAPT
SCHEMBL5325948 0.69 MAPT (0.47) TP53POLBLMNAL3MBTL1RAB9A
SCHEMBL3720870 0.69 MAPT (0.47) POLBMAPTMEN1KMT2AALDH1A1
SCHEMBL21412593 0.68 POLB (0.45) POLBLMNAL3MBTL1RAB9AMAPT
SCHEMBL12651849 0.68 HTT (0.61) TP53POLBLMNARAB9AMAPT
SCHEMBL15080780 0.67 HPGD (0.52) LMNARAB9AMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1637527-B1 CANNABINOID RECEPTOR MODULATOR TAKEDA PHARMACEUTICAL (JP) 2013-04-17 — — EP disclosed
US-20100240743-A1 CANNABINOID RECEPTOR MODULATOR TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-23 — — US disclosed
US-7507841-B2 Carbamoylamino-substituted 2,3-dihydro-benzofurans, indoles and benzothiophenes, e.g., (+)-N-((3R)-3-(4-isopropylphenyl)-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide; cerebrovascular disorders TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-03-24 — — US disclosed
US-20090023800-A1 Cannabinoid receptor modulator TAKEDA PHARMACEUTICAL COMPANY LIMITED 2009-01-22 — — US disclosed
US-7465815-B2 Cannabinoid receptor modulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-16 — — US disclosed
US-20080021087-A1 Cannabinoid receptor modulator TAKEDA PHARMACEUTICAL COMPANY LIMITED 2008-01-24 — — US disclosed
US-20070099990-A1 Cannabinoid receptor modulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-05-03 — — US disclosed
EP-1637527-A1 CANNABINOID RECEPTOR MODULATOR Takeda Pharmaceutical Company Limited (JP) 2006-03-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240743-A1 CANNABINOID RECEPTOR MODULATOR CNR1, CNR2, GPR18 TP53 4621/4885POLB 3511/4885LMNA 4417/4885
US-20080021087-A1 Cannabinoid receptor modulator CNR1, CNR2, GPR18 TP53 4621/4885POLB 3511/4885LMNA 4417/4885
US-20090023800-A1 Cannabinoid receptor modulator CNR1, CNR2, GPR18 TP53 4621/4885POLB 3511/4885LMNA 4417/4885
US-20070099990-A1 Cannabinoid receptor modulator CNR1, CNR2, GPR18 TP53 4621/4885POLB 3511/4885LMNA 4417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback